J Biol Chem, Vol. 273, Issue 32, 20238-20242, August 7, 1998
Carboxymethyl-phenylalanine as a Replacement for Phosphotyrosine
in SH2 Domain Binding
Liang
Tong,
Thomas C.
Warren,
Susan
Lukas,
Josephine
Schembri-King,
Raj
Betageri,
John R.
Proudfoot, and
Scott
Jakes
From Boehringer Ingelheim Pharmaceuticals, Inc.,
Ridgefield, Connecticut 06877
The crystal structure of human p56lck SH2
domain in complex with an inhibitor containing the singly charged
p-(carboxymethyl)phenylalanine residue (cmF) as a
phosphotyrosine (Tyr(P) or pY) replacement has been determined at 1.8 Å resolution. The binding mode of the acetyl-cmF-Glu-Glu-Ile (cmFEEI)
inhibitor is very similar to that of the pYEEI inhibitor, confirming
that the cmFEEI inhibitor has a similar mechanism of SH2 domain
inhibition despite its significantly reduced potency. Observed
conformational differences in the side chain of the cmF residue can be
interpreted in terms of maintaining similar interactions with the SH2
domain as the Tyr(P) residue. The crystal structure of the free
p56lck SH2 domain has been determined at 1.9 Å resolution and
shows an open conformation for the BC loop and an open phosphotyrosine binding pocket, in contrast to earlier studies on the src
SH2 domain that showed mostly closed conformation. The structural information presented here suggests that the
carboxymethyl-phenylalanine residue may be a viable Tyr(P) replacement
and represents an attractive starting point for the design and
development of SH2 domain inhibitors with better pharmaceutical
profiles.
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.